Please ensure Javascript is enabled for purposes of website accessibility

Does Vaxart Still Have a Future?

By Keith Speights and Brian Orelli, PhD - Feb 10, 2021 at 8:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The short answer: Yes.

Vaxart (VXRT 2.44%) recently reported preliminary results from phase 1 study of its tablet COVID-19 vaccine candidate. Although there were some positive data in those results, many investors worried about the failure of the experimental vaccine to produce neutralizing antibodies in study participants. The biotech stock plunged after the clinical update. In this Motley Fool Live video recorded on Feb. 3, 2021, contributors Keith Speights and Brian Orelli answer a viewer's question about whether Vaxart still has a future.

Keith Speights: JP asked, "Any future left for Vaxart?"

Brian Orelli: I think, you read down, it's a $1.4 billion market cap. That seems high to me for now. Very uncertain future. So whether it has no future, I don't know that I would say that, but I would be definitely concerned at buying right now based on the $1.4 billion market cap.

I think that probably tells me maybe other people think I'm wrong because that's pretty high valuation for some unproven technology. I'd say I don't think so, but it probably, it's worth looking into it based on the fact that other people do, and I don't pretend to be the smartest person on Wall Street.

Speights: I agree with you. I think it's too strong of a statement to say Vaxart has no future. I don't think that's necessarily the case. They do have other pipeline candidates. They've had some promise with another experimental tablet vaccine. It's just still really early, so I wouldn't write off the company, but I do agree with you that after today's news, the future for Vaxart doesn't look nearly as promising as it might have before today.

Orelli: I guess the biggest question is, is this problem-specific to coronavirus, or is it just specific to their tablet? If it's specific to their tablet, then I think it's probably overvalued and if it's specific to the coronavirus, then maybe it's not overvalued and it's a reasonable valuation.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
$3.78 (2.44%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.